| |
| Issue |
Title |
| |
| No 6 (2025) |
The value of genome-wide association studies and genetic risk scales for predicting type 2 diabetes mellitus, its complications, and pharmacogenetics |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, V. V. Titova |
| |
| No 6 (2025) |
Practical application of semaglutide: From evidence-based research to expert decisions |
Abstract
PDF (Rus)
PDF (Eng)
|
|
V. V. Salukhov, G. R. Galstyan, Iu. Sh. Khalimov, I. G. Bakulin, D. V. Cherkashin, F. E. Shadrichev, N. A. Sukhotskaia |
| |
| No 6 (2025) |
Remote monitoring of blood glucose self-control: Potential in the treatment of type 2 diabetes |
Abstract
PDF (Rus)
|
|
L. A. Suplotova, O. O. Alieva, A. A. Golubeva, A. I. Lyapunova |
| |
| No 6 (2025) |
All-Russian observational non-interventional program on the study of the efficacy of Subetta in real-world clinical practice in patients with prediabetes (SILA) |
Abstract
PDF (Rus)
|
|
A. V. Zilov, L. Z. Bolieva |
| |
| No 6 (2025) |
Alteration of gut microbiota composition in patients with prediabetes and type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
O. A. Myrinova, A. A. Tulsky, A. O. Shchetinina, N. S. Martirosian, I. A. Kuzina, E. V. Goncharova, M. E. Telnova, E. A. Elmurzaeva, N. A. Petunina |
| |
| No 6 (2025) |
Digital technologies in self-monitoring of blood glucose and their clinical significance |
Abstract
PDF (Rus)
|
|
I. N. Grigor’eva, N. L. Tov |
| |
| No 16 (2024) |
Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke |
Abstract
PDF (Rus)
|
|
T. L. Karonova, A. V. Murasheva, N. V. Timkina, O. S. Fuks, E. V. Shlyakhto |
| |
| No 16 (2024) |
Glucosuria as a major mechanism-associated effect of sodium-glucose cotransporter 2 inhibitors: Is there cause for concern? |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, M. Ya. Izmaylova |
| |
| No 16 (2024) |
Modern aspects of therapy of metabolic associated liver disease in patients with type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
S. V. Bulgakova, Yu. A. Dolgikh, L. A. Sharonova, O. V. Kosareva, E. V. Treneva, P. Ya. Merzlova, D. P. Kurmayev |
| |
| No 16 (2024) |
Vector of glycated hemoglobin in the formation of dysglycemia in postmenopause: Emphasis on early diagnosis and therapy |
Abstract
PDF (Rus)
|
|
L. A. Ruyatkina, D. S. Ruyatkin, L. V. Shcherbakova, I. S. Iskhakova |
| |
| No 16 (2024) |
Changes in skeletal muscle in diabetes mellitus |
Abstract
PDF (Rus)
|
|
O. A. Shatskaya, I. Z. Bondarenko, S. S. Kushnarenko |
| |
| No 16 (2024) |
The short- and long-term results of therapy of surgical diabetic foot patients |
Abstract
PDF (Rus)
|
|
V. V. Salukhov, T. A. Zelenina, K. S. Akhmedova, D. A. Mereschenko, D. D. Ismailov, A. N. Lipin, A. G. Borisov, I. M. Khokhlova |
| |
| No 6 (2024) |
Collaboration of alogliptin and pioglitazone: a double hit on the target |
Abstract
PDF (Rus)
|
|
V. V. Salukhov, E. A. Kovalevskaya, Т. A. Ilyinskaya |
| |
| No 6 (2024) |
Priorities of self-monitoring of glycemia: an important component of successful diabetes management |
Abstract
PDF (Rus)
|
|
E. V. Biryukova, М. V. Shinkin |
| |
| No 6 (2024) |
Insulin therapy for elderly patients with type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
N. A. Petunina, I. A. Kuzina, M. E. Telnova, E. V. Goncharova, N. S. Martirosyan, A. O. Shchetinina, M. V. Khachaturov |
| |
| No 9 (2023) |
A safe approach to the treatment of type 2 diabetes in elderly patients |
Abstract
PDF (Rus)
|
|
S. V. Bulgakova, S. A. Bashinskaya, Y. A. Dolgikh, L. A. Sharonova, O. V. Kosareva, E. V. Treneva, D. P. Kurmayev, I. I. Sirotko |
| |
| No 9 (2023) |
Neuroprotective potential of incretinomimetics |
Abstract
PDF (Rus)
|
|
A. S. Kokin, L. A. Suplotova, T. S. Dushina, O. B. Makarova |
| |
| No 9 (2023) |
The role of triglyceride-glucose index in predicting cardiovascular and metabolic outcomes in patients with type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, M. Ya. Izmaylova, K. M. Belova |
| |
| No 9 (2023) |
Cardiac autonomic neuropathy as risk factor of diabetic complications progression |
Abstract
PDF (Rus)
|
|
V. V. Salukhov, T. A. Zelenina, D. D. Ismailov, A. B. Zemlianoi |
| |
| No 9 (2023) |
The use of stem cells and 3D bioprinting of pancreatic islets in the treatment of type 1 diabetes mellitus: history and perspectives |
Abstract
PDF (Rus)
|
|
S. V. Bulgakova, Y. A. Dolgikh, E. V. Treneva, L. A. Sharonova, O. V. Kosareva, D. P. Kurmaev |
| |
| No 9 (2023) |
Characteristics of glucose variability in different types of diabetes mellitus in young patients |
Abstract
PDF (Rus)
|
|
A. K. Ovsyannikova, M. V. Dudina, R. B. Galenok, A. O. Antonova, O. D. Rymar |
| |
| No 9 (2023) |
Glycemia control using remote technologies |
Abstract
PDF (Rus)
|
|
L. A. Suplotova, O. O. Alieva |
| |
| No 9 (2023) |
Innovative technologies in the management of diabetes mellitus: prevention of hypoglycemia |
Abstract
PDF (Rus)
|
|
O. V. Svetlova, I. V. Gurieva |
| |
| No 9 (2023) |
Approaches to switching between insulin product with different insulin active substance |
Abstract
PDF (Rus)
|
|
T. Y. Demidova, M. A. Dranitsyna, R. R. Niyazov, A. N. Vasiliev, E. V. Gavrishina |
| |
| No 9 (2023) |
Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment |
Abstract
PDF (Rus)
|
|
E. V. Biryukova, D. V. Kileynikov |
| |
| No 10 (2022) |
Dietary fiber is a reliable and apparent element of treatment for patients with type 2 diabetes mellitus and cardiovascular diseases: an easy solution to a complicated problem |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, T. N. Korotkova, A. S. Kochina |
| |
| No 10 (2022) |
Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent |
Abstract
PDF (Rus)
|
|
V. V. Salukhov, E. A. Kovalevskaya |
| |
| No 10 (2022) |
Special considerations in the therapeutic education of elderly with diabetes mellitus type 2 |
Abstract
PDF (Rus)
|
|
A. V. Balashova, I. V. Glinkina, M. G. Pavlova, A. V. Oderiy, V. V. Fadeev |
| |
| No 10 (2022) |
Metabolic and cardiovascular features of the course of type 2 diabetes mellitus in men with hypogonadism |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, D. V. Skuridina, A. M. Kasimova |
| |
| No 10 (2022) |
Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review) |
Abstract
PDF (Rus)
|
|
E. A. Ortenberg, L. A. Suplotova |
| |
| No 10 (2022) |
Possible clinical applications of knowledge about the genetics of type 2 diabetes |
Abstract
PDF (Rus)
PDF (Eng)
|
|
T. Yu. Demidova, V. M. Plakhotnyaya |
| |
| No 10 (2022) |
Features of the course of type 2 diabetes mellitus in young people |
Abstract
PDF (Rus)
|
|
A. K. Ovsyannikova, A. Yu. Zubareva |
| |
| No 10 (2022) |
Comparison efficacy of different regimens of insulin therapy in patients with type 2 diabetes and morbid obesity |
Abstract
PDF (Rus)
|
|
E. S. Maloletkina, O. Y. Gurova, I. V. Glinkina, M. V. Amosova, Zh. Zh. Shyman, I. A. Khaykina, M. F. Kalashnikova, V. V. Fadeev |
| |
| No 10 (2022) |
Study of equivalence and comparable immunogenicity of biosimilar insulin aspart in comparison with the registered analogue |
Abstract
PDF (Rus)
|
|
Т. L. Karonova, A. Y. Mayorov |
| |
| No 10 (2022) |
Influence of gut microbiota on the development of insulin resistance |
Abstract
PDF (Rus)
PDF (Eng)
|
|
T. Yu. Demidova, K. G. Lobanova, N. S. Shevtsova, T. N. Korotkova, A. S. Kochina |
| |
| No 10 (2022) |
Metformin in prediabetes: key mechanisms for the prevention of diabetes and cardiometabolic risks |
Abstract
PDF (Rus)
|
|
A. Yu. Babenko |
| |
| No 7 (2021) |
Fast-acting insulin aspart - from insulin portraits to patient portraits |
Abstract
PDF (Rus)
|
|
T. Yu. Demidova, M. Ya. Izmaylova |
| |
| No 7 (2021) |
Efficacy of dulaglutide: an evidence-based review of its potential indications |
Abstract
PDF (Rus)
|
|
E. V. Biryukova, I. V. Solovyeva |
| |
| No 7 (2021) |
Analysis of the formation of dysglycemia in the substantiation of early pathogenetic therapy of diabetes mellitus |
Abstract
PDF (Rus)
|
|
L. A. Ruyatkina, D. S. Ruyatkin, I. S. Iskhakova |
| |
| No 7 (2021) |
Analysis of time in range depending on the method of assessing the glucose level |
Abstract
PDF (Rus)
|
|
L. A. Suplotova, A. S. Sudnitsyna, N. V. Romanova, K. A. Sidorenko, L. U. Radionova, T. V. Gracheva, N. V. Plotnikov, E. V. Khieva, O. Y. Shabelnikova, I. A. Ipatko, G. V. Zhukovets, M. A. Cherednikova |
| |
| No 7 (2021) |
Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
I. V. Glinkina, A. V. Balashova, A. S. Shyman, A. V. Oderij, S. A. Khan, G. E. Runova, T. B. Morgunova, V. V. Fadeev |
| |
| No 7 (2020) |
Dipeptidyl peptidase 4 inhibitors in modern domestic practice |
Abstract
PDF (Rus)
|
|
A. S. Ametov, N. A. Chernikov, O. A. Knyshenko |
| |
| No 7 (2020) |
“Hepatogenic diabetes” is an old term and new meaning |
Abstract
PDF (Rus)
|
|
Yu. Kokovina, E. Yu. Pavlova, E. A. Antonova |
| |
| No 7 (2020) |
Possibilities of using continuous glycemic monitoring to assess the effectiveness of therapy in patients with MODY-diabetes |
Abstract
PDF (Rus)
|
|
A. K. Ovsyannikova, M. V. Ryabets, O. D. Rymar |
| |
| No 7 (2020) |
New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes |
Abstract
PDF (Rus)
|
|
V. V. Salukho, T. A. Ilyinskay |
| |
| No 7 (2020) |
Alogliptin: efficiency, safety, new possibilities |
Abstract
PDF (Rus)
|
|
L. Yu. Morgunov |
| |
| No 7 (2020) |
Glucagon-like peptide-1 receptor agonists, selection within the class. The rational combination of insulin glargine 100 + lixisenatide |
Abstract
PDF (Rus)
|
|
M. V. Martjanova, A. Yu. Babenko |
| |
| No 4 (2019) |
Combination versus monotherapy with statins in patients with type 2 diabetes mellitus of high and very high cardiovascular risk |
Abstract
PDF (Rus)
|
|
Y. A. Sorokina, A. D. Postnikova, O. V. Zanozina, L. V. Lovcova |
| |
| No 4 (2019) |
Clinical aspects and prospects of using DPP-4 inhibitors |
Abstract
PDF (Rus)
|
|
E. V. Biryukova |
| |
| No 4 (2019) |
Modern strategies for self-monitoring: new era of effective diabetes management |
Abstract
PDF (Rus)
|
|
O. V. Svetlova, I. V. Guryeva, L. S. Savchenko |
| |
| No 4 (2019) |
New opportunities for injecting therapy of type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
Editorial article |
| |
| No 4 (2019) |
The modern paradigm for assessment of the integral parameters аnd the glycemic variability - the role for the type 2 diabetes mellitus management |
Abstract
PDF (Rus)
|
|
N. A. Chernikova, L. L. Kamynina, A. S. Ametov |
| |
| No 4 (2019) |
The results and the meaning of EMPA-REG OUTCOME and LEADER studies for modern diabetology: in search of ideal combination |
Abstract
PDF (Rus)
|
|
V. V. Salukhov |
| |
| No 4 (2019) |
Modern aspects for preventive therapy of type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
V. V. Salukhov, B. V. Romashevsky |
| |
| No 4 (2019) |
Sitagliptin: the world’s first DPP-4 inhibitor |
Abstract
PDF (Rus)
|
|
N. A. Petunina, E. V. Goncharova, M. E. Telnova, L. V. Trukhina, N. S. Martirosyan |
| |
| No 4 (2018) |
Development of carbohydrate metabolism disorder from the perspective of chronobiology |
Abstract
PDF (Rus)
|
|
A. E. Yuzhakova, A. A. Nelaeva, Yu. V. Khasanova |
| |
| No 4 (2018) |
Efficacy and safety of dulaglutide: a novel once-weekly glucagon-like peptide-1 analogue |
Abstract
PDF (Rus)
|
|
A. S. Pogorelova, V. V. Fadeev |
| |
| No 4 (2018) |
Management of type 2 diabetes mellitus: selecting the right of antihyperglycemic medication |
Abstract
PDF (Rus)
|
|
E. V. Biryukova |
| |
| No 4 (2018) |
Modern approaches to the treatment of type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
T. V. Morgunova, V. V. Fadeev |
| |
| No 4 (2018) |
Metformin is the most recognized first choice drug for patients with type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
A. M. Mkrtumyan |
| |
| No 4 (2018) |
Pancreatogenic diabetes / type 3c diabetes: status update on the problem |
Abstract
PDF (Rus)
|
|
L. A. Ruiatkina, D. S. Ruiatkin |
| |
| No 3 (2017) |
PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN |
Abstract
PDF (Rus)
|
|
V. K. Bayrasheva, A. Y. Babenko, A. A. Bayramov, S. G. Chefu, I. S. Shatalov, I. Y. Pchelin, A. N. Arefieva, E. N. Grineva |
| |
| No 3 (2017) |
DIABETES MANAGEMENT AND CURRENT PROSPECTS FOR SELF-MONITORING OF BLOOD GLUCOSE |
Abstract
PDF (Rus)
|
|
E. V. Goncharova, N. A. Petunina |
| |
| No 3 (2017) |
ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE |
Abstract
PDF (Rus)
|
|
Y. S. Khalimov, P. V. Agafonov, V. G. Kuzmich |
| |
| No 3 (2017) |
CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN |
Abstract
PDF (Rus)
|
|
N. A. Petunina, E. V. Goncharova, S. A. Potapova |
| |
| No 3 (2017) |
A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES |
Abstract
PDF (Rus)
|
|
M. V. Amosova, V. V. Fadeev |
| |
| No 3 (2016) |
The role of sulfonylures in the treatment of type 2 diabetes |
Abstract
PDF (Rus)
|
|
L. A. Sharonova, A. F. Verbovoy, O. V. Kosareva |
| |
| No 3 (2016) |
SGLT2: new approaches to combination therapy of type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
I. V. Kononenko, O. M. Smirnova |
| |
| No 3 (2016) |
Place of insulin therapy in current approaches to the treatment of type 2 diabetes |
Abstract
PDF (Rus)
|
|
O. Y. Gurova, V. V. Fadeev |
| |
| No 3 (2016) |
Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
Abstract
PDF (Rus)
|
|
E. V. Biryukova, A. M. Mkrtumyan |
| |
| No 3 (2016) |
The efficacy of metformin in the treatment of type 2 diabetes |
Abstract
PDF (Rus)
|
|
А. S. Ametov, T. Y. Demidova, I. I. Kochergina |
| |
| 1 - 71 of 71 Items |
|
